Uno studio di prima somministrazione nell'uomo di BG-C0979 in adulti con tumori solidi avanzati
Uno Studio Multicentrico, in Aperto, di Fase 1a/b, Primo nell'Uomo, per Indagare la Sicurezza, la Tollerabilità, la Farmacocinetica e l'Attività Antitumorale Preliminare di BG-C0979 in Pazienti con Tumori Solidi Avanzati Selezionati
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of BG-C0979 monotherapy or in combination with tislelizumab in participants with selected advanced solid tumors. The study will consist of Phase 1a (Dose Escalation and Safety Expansion) and Phase 1b (Dose Expansion).
Panoramica dello studio
Stato
Condizioni
Intervento / Trattamento
Tipo di studio
Iscrizione (Stimato)
Fase
- Fase 1
Contatti e Sedi
Contatto studio
- Nome: Study Director
- Numero di telefono: 8778285568
- Email: clinicaltrials@beonemed.com
Luoghi di studio
-
-
New South Wales
-
Frenchs Forest, New South Wales, Australia, NSW 2086
- Reclutamento
- Northern Beaches Hospital
-
Liverpool, New South Wales, Australia, NSW 2170
- Reclutamento
- Liverpool Hospital
-
-
Queensland
-
South Brisbane, Queensland, Australia, QLD 4101
- Reclutamento
- Icon Cancer Centre South Brisbane
-
-
Victoria
-
Malvern, Victoria, Australia, VIC 3144
- Reclutamento
- Cabrini Hospital Malvern
-
-
-
-
Beijing Municipality
-
Beijing, Beijing Municipality, Cina, 100021
- Reclutamento
- Cancer Hospital Chinese Academy of Medical Sciences
-
-
Chongqing Municipality
-
Chongqing, Chongqing Municipality, Cina, 400037
- Reclutamento
- Second Affiliated Hospital of Army Medical University (Xinqiao Hospital)
-
-
Fujian
-
Fuzhou, Fujian, Cina, 350028
- Reclutamento
- Mengchao Hepatobiliary Hospital of Fujian Medical University
-
-
Guangdong
-
Guangzhou, Guangdong, Cina, 510245
- Reclutamento
- Sun Yat Sen Memorial Hospital, Sun Yat Sen University (South)
-
-
Hubei
-
Yichang, Hubei, Cina, 443003
- Reclutamento
- Yichang Central Peoples Hospital
-
-
Shanghai Municipality
-
Shanghai, Shanghai Municipality, Cina, 201321
- Reclutamento
- Fudan University Shanghai Cancer Centerpudong
-
-
-
-
-
Barcelona, Spagna, 08036
- Reclutamento
- Hospital Clinic de Barcelona
-
Barcelona, Spagna, 08035
- Reclutamento
- Hospital Universitario Vall Dhebron
-
Madrid, Spagna, 28040
- Reclutamento
- Hospital Universitario Fundacion Jimenez Diaz
-
Madrid, Spagna, 28223
- Reclutamento
- Next Oncology Madrid
-
-
-
-
Massachusetts
-
Boston, Massachusetts, Stati Uniti, 02215-5418
- Reclutamento
- Dana Farber Cancer Institute
-
-
Missouri
-
St Louis, Missouri, Stati Uniti, 63110-1010
- Reclutamento
- Washington University School of Medicine
-
-
New Jersey
-
Hackensack, New Jersey, Stati Uniti, 07601
- Reclutamento
- John Theurer Cancer Center Hackensack University Medical Center
-
-
Texas
-
San Antonio, Texas, Stati Uniti, 78229
- Reclutamento
- Next Oncology San Antonio
-
-
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Inclusion Criteria:
- Phase 1a (Monotherapy Dose Escalation and Safety Expansion): Participants with histologically or cytologically confirmed advanced, metastatic, and unresectable solid tumors who have previously received standard systemic therapy or for whom treatment is not available or not tolerated, or determined not appropriate based on investigator's judgment.
- Phase 1b Part A (Monotherapy Dose Optimization and Expansion): Participants with histologically or cytologically confirmed advanced, metastatic, and unresectable solid tumors who have previously received standard systemic therapy or for whom treatment is not available or not tolerated, or determined not appropriate based on investigator's judgment.
- Phase 1b Part B (Combination Therapy Expansion): Participants with histologically or cytologically confirmed metastatic or unresectable advanced solid tumors who have not received any prior systemic treatment for advanced or metastatic disease.
- Participants must have ≥ 1 measurable lesion as assessed by RECIST v1.1.
- Participants must have a stable Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1.
- Participants must have adequate organ function.
Exclusion Criteria:
- Prior treatment with any ADAM9 (a disintegrin and metalloproteinase domain 9)-targeted antibody-drug conjugates (ADCs) or ADCs containing TOPO1 (DNA topoisomerase 1) inhibitor as payload.
- Active leptomeningeal disease or uncontrolled, untreated brain metastasis.
Note: Other protocol defined Inclusion/Exclusion criteria may apply.
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Trattamento
- Assegnazione: Non randomizzato
- Modello interventistico: Assegnazione sequenziale
- Mascheramento: Nessuno (etichetta aperta)
Armi e interventi
Gruppo di partecipanti / Arm |
Intervento / Trattamento |
|---|---|
|
Sperimentale: Phase 1a: Monotherapy Dose Escalation
Participants will receive increasing doses of BG-C0979 as monotherapy. |
Administered by intravenous infusion. |
|
Sperimentale: Phase 1a: Monotherapy Safety Expansion
Participants will receive BG-C0979 as monotherapy. Selected dose levels that have been determined to be safe in Phase 1a dose escalation will be further evaluated in safety expansion. |
Administered by intravenous infusion. |
|
Sperimentale: Phase 1b, Part A: Monotherapy Dose Optimization and Dose Expansion
Participants will receive BG-C0979 as monotherapy in a dose optimization and dose expansion phase at different dose levels of recommended doses for expansion (RDFEs) identified in Phase 1a. |
Administered by intravenous infusion. |
|
Sperimentale: Phase 1b, Part B: Combination Therapy Expansion
Participants will receive BG-C0979 in combination with tislelizumab in select tumor types. |
Administered by intravenous infusion. Administered by intravenous infusion.
Altri nomi:
|
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Phase 1a: Number of Participants Experiencing Adverse Events (AEs)
Lasso di tempo: Up to approximately 24 months
|
Number of participants with treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs), including dose limiting toxicities (DLTs), AEs meeting protocol-defined adverse event of clinical interest (AECI) criteria, laboratory values, and electrocardiogram results. |
Up to approximately 24 months
|
|
Phase 1a: Maximum Tolerated Dose (MTD) or Maximum Administered Dose (MAD) of BG-C0979 Monotherapy
Lasso di tempo: Up to approximately 10 months
|
MTD or MAD, defined as the highest dose for which the estimated toxicity rate is closest to the target toxicity rate of 28%, or the highest dose administered, respectively. |
Up to approximately 10 months
|
|
Phase 1a: Recommended Dose(s) for Expansion (RDFE[s])
Lasso di tempo: Up to approximately 10 months
|
The potential RDFE(s) of BG-C0979 will be determined based on the totality of data including the MTD or MAD, long-term tolerability, pharmacokinetics (PK), preliminary antitumor activity, and any other relevant data, as available. |
Up to approximately 10 months
|
|
Phase 1b: Recommended Phase 2 Dose (RP2D)
Lasso di tempo: Up to approximately 24 months
|
RP2D of BG-C0979 alone and in combination with tislelizumab will be determined based on safety, PK, preliminary antitumor activity, and other relevant data, as available. |
Up to approximately 24 months
|
|
Phase 1b: Overall Response Rate (ORR)
Lasso di tempo: Up to approximately 24 months
|
ORR as determined from tumor assessment by the investigator using Response Evaluation Criteria in Solid Tumors (RECIST) v1.1. For castration-resistant prostate cancer (CRPC), ORR will be assessed by RECIST v1.1 criteria for soft tissue and Prostate Cancer Clinical Trials Working Group 3 (PCWG3) criteria for bone lesions. ORR is defined as the percentage of participants with best overall response of a complete response (CR) or partial response (PR). |
Up to approximately 24 months
|
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Fase 1a: Concentrazione plasmatica di BG-C0979
Lasso di tempo: Fino a circa 3 mesi
|
Fino a circa 3 mesi
|
|
|
Fase 1a: Area Sotto la Curva Concentrazione-Tempo (AUC) per BG-C0979
Lasso di tempo: Fino a circa 3 mesi
|
Fino a circa 3 mesi
|
|
|
Fase 1a: Concentrazione Massima Osservata (Cmax) di BG-C0979
Lasso di tempo: Fino a circa 3 mesi
|
Fino a circa 3 mesi
|
|
|
Fase 1a: Tempo per Raggiungere la Concentrazione Massima (Tmax) di BG-C0979
Lasso di tempo: Fino a circa 3 mesi
|
Fino a circa 3 mesi
|
|
|
Fase 1b: Concentrazione plasmatica di BG-C0979, da solo e in combinazione con Tislelizumab
Lasso di tempo: Fino a circa 3 mesi
|
Fino a circa 3 mesi
|
|
|
Phase 1a: ORR
Lasso di tempo: Up to approximately 24 months
|
ORR as determined from tumor assessment by the investigator using RECIST v1.1. For CRPC, ORR will be assessed by RECIST v1.1 criteria for soft tissue and PCWG3 criteria for bone lesions. ORR is defined as the percentage of participants with best overall response of a complete response (CR) or partial response (PR). |
Up to approximately 24 months
|
|
Phase 1a and 1b: Duration of Response (DOR)
Lasso di tempo: Up to approximately 24 months
|
DOR as determined from tumor assessment by the investigator using RECIST v1.1. For CRPC, DOR will be assessed by RECIST v1.1 criteria for soft tissue and PCWG3 criteria for bone lesions. DOR is defined as the time from the first determination of an objective response until the first documentation of disease progression or death due to any cause, whichever occurs first. |
Up to approximately 24 months
|
|
Phase 1a and 1b: Disease Control Rate (DCR)
Lasso di tempo: Up to approximately 24 months
|
DCR as determined from tumor assessment by the investigator using RECIST v1.1. For CRPC, DCR will be assessed by RECIST v1.1 criteria for soft tissue and PCWG3 criteria for bone lesions. DCR is defined as the percentage of participants with best overall response of a CR, PR, or stable disease. |
Up to approximately 24 months
|
|
Phase 1b: Number of Participants Experiencing Adverse Events (AEs)
Lasso di tempo: Up to approximately 24 months
|
Number of participants with TEAEs and SAEs, including AECIs, laboratory values, and electrocardiogram results. |
Up to approximately 24 months
|
|
Phase 1b: Progression-Free Survival
Lasso di tempo: Up to approximately 24 months
|
PFS is defined as the time from the date of the first administration of study drug(s) to the date of the first documentation of disease progression or death due to any cause, whichever occurs first. |
Up to approximately 24 months
|
|
Phase 1b: Radiographic Progression-Free Survival (rPFS) for Participants with CRPC
Lasso di tempo: Up to approximately 24 months
|
rPFS is defined as the time from the date of the first administration of study drug(s) to the date of the first objective evidence of radiographic disease progression or death due to any cause, whichever occurs first. |
Up to approximately 24 months
|
|
Prostate-Specific Antigen (PSA) Response for Participants with CRPC
Lasso di tempo: Up to approximately 24 months
|
PSA response is defined as a ≥50% decrease in PSA level from baseline to the lowest post-baseline PSA result, confirmed by a second consecutive PSA assessment at least 3 weeks later. |
Up to approximately 24 months
|
Collaboratori e investigatori
Sponsor
Investigatori
- Direttore dello studio: Study Director, BeOne Medicines
Studiare le date dei record
Studia le date principali
Inizio studio (Effettivo)
Completamento primario (Stimato)
Completamento dello studio (Stimato)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Termini MeSH pertinenti aggiuntivi
Altri numeri di identificazione dello studio
- BG-C0979-101
- 2025-524857-15-00 (Ctis)
- CTR20261327 (Altro identificatore: ChinaDrugTrials)
- 2025 (Sovvenzione/contratto NIH degli Stati Uniti)
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
Descrizione del piano IPD
BeOne shares data on completed studies responsibly and provides qualified scientific and medical researchers access to data and supporting documentation for clinical trials in dossiers for medicines and indications after submission and approval in the United States, China, and Europe. Clinical trials supporting subsequent local approvals, new indications, or combination products are eligible for sharing once corresponding regulatory approvals are achieved.
BeOne shares data only when permitted by applicable data privacy and security laws and regulations, when it is feasible to do so without compromising the privacy of study participants, and other considerations.
Qualified researchers with appropriate competencies who are engaged in novel scientific research may submit a request for participant-level data with a research proposal for BeOne review. Research teams must include a biostatistician and sign a Data Sharing Agreement prior to receiving access to clinical trial data.
Periodo di condivisione IPD
See plan description
Criteri di accesso alla condivisione IPD
See plan description
Tipo di informazioni di supporto alla condivisione IPD
- STUDIO_PROTOCOLLO
- LINFA
- RSI
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .